Current Opinion in Oncology· 2026Q2· Review
Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma
- 0citations
- Q2SCImago
- 2026year
Short summary
Targeted therapies, particularly IDH1/2 inhibition with vorasidenib, show promise in reducing seizure frequency in glioma patients, with the INDIGO trial reporting a 0.36 rate ratio for on-treatment seizures vs. placebo.
AI-generated from the title and abstract; the full text is not read.
Key points
- Vorasidenib, an IDH1/2 inhibitor, reduced on-treatment seizure rates by 64% (rate ratio 0.36) compared to placebo in glioma patients (INDIGO trial).
- Real-world data and case reports support the antiseizure effects of targeted therapies, with some evidence suggesting independence from tumor control.
- BRAF/MEK and mTOR inhibitors have established antitumour roles and have shown seizure reduction in specific tumor types (e.g., tuberous sclerosis complex).
- Future clinical trials must formally assess seizure freedom as a prespecified endpoint for targeted therapies in glioma.
AI-generated from the title and abstract; the full text is not read.
Abstract
PURPOSE OF REVIEW: Seizures are among the most frequent and disabling manifestations of gliomas, and in some patients remain drug-resistant despite optimal antiseizure medication and standard antitumour treatments. This review examines the clinical evidence that targeted therapies may improve seizure control in patients with glioma. RECENT FINDINGS: The strongest signal comes from mutant isocitrate dehydrogenase (IDH1/2) inhibition. In the phase 3 INDIGO trial, exploratory and posthoc analyses showed an on-treatment seizure rate of 18.2 per person-year with vorasidenib vs. 51.2 with placebo [rate ratio 0.36, 95% confidence interval (CI) 0.14-0.89]. Emerging real-world series and individual case reports support these findings, and preclinical work indicates an antiseizure effect at least partly independent of tumour control. BRAF/MEK inhibition and mTOR inhibition have an established antitumour role in circumscribed astrocytic and glioneuronal tumours, and everolimus reduces both tumour volume and pharmacoresistant seizures in tuberous sclerosis complex. Beyond genotype, the shared circuitry of tumourigenesis and epileptogenesis, such as neuron-glioma synapses, has generated a second wave of candidate targets, none yet clinically validated. SUMMARY: Targeted agents are emerging as disease-modifying options that may also reduce seizure burden, but seizure freedom must be tested in future trials as a prespecified endpoint rather than inferred from exploratory analyses.
The authors' abstract, as published at the source. Current Opinion in Oncology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Genetics (Medicine)
GeneticsMedicine